NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nutcracker Therapeutics

Nutcracker Therapeutics

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttp://nutcrackerx.com/

Last Round

Series C

Mar 14, 2022

Total Funding Raised

$241M

Company Overview

Nutcracker Therapeutics is a biotechnology company that develops mRNA-based therapeutic drug products through its innovative platform that integrates proprietary hardware, software, and advancements in mRNA biochemistry and nanoparticle delivery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Smart Manufacturing, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Infrastructure

Keywords

mRNA therapeuticsCRDMObiochip manufacturingcontract research organizationbiomanufacturingpersonalized cancer vaccinesmicrofluidicsmRNA drug developmentlab-on-a-chipnanoparticle deliverybiotech automationRNA designdrug manufacturing platformbiopharma servicesprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nutcracker Therapeutics Comparables

Compare Nutcracker Therapeutics with similar companies based on industry and business-model similarity.

Nutcracker Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
eTheRNA
81%
Univercells
81%
Dillico
71%

Nutcracker Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 14, 2022
Series BSep 23, 2020
Series AMar 21, 2019
SeedMay 17, 2018

Nutcracker Therapeutics Investors

Notable investors and investment history

Nutcracker Therapeutics investors
InvestorRounds
Altitude Life Science VenturesSeries C, Series A
ARCH Venture PartnersSeries A, Series B, Series C
ARCH Venture PartnersSeries B, Series C
Bluebird VenturesSeries B, Series C, Series A
Sutter Hill VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 26, 2025

    Cynthia Collins appointed Executive Chair and Interim CEO.

  • Sep 23, 2020

    $60M round led by ARCH Venture Partners.

Nutcracker Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nutcracker Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nutcracker Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range46
Year Founded2018
Last FundingMar 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.